SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is witnessing significant volatility amid recent CME margin hikes and widespread discussions surrounding upcoming Chinese export restrictions. The community is sharply divided between bullish investors anticipating an explosive rally driven by industrial demand and supply concerns, and bearish traders who warn of a speculative "pump and dump" and an unsustainable price bubble. This fierce debate highlights the ongoing battle between paper market dynamics and long-term fundamental perspectives.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is actively trending as its position as 'Bitcoin's Digital Silver Cousin' draws significant retail attention, with recent news highlighting its market performance. The community is buzzing with anticipation, discussing upcoming developments like the LitVM airdrop and technical chart setups, even as some express frustration over persistent resistance levels. Sentiment remains divided between those expecting a major breakout and those observing market manipulation, while also noting its enhanced privacy features with MWEB and Omnichain.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

DOG is trending as its dedicated 'DOG Army' passionately advocates for its position as the leading Bitcoin-native memecoin, highlighting its unique permanence and direct link to Bitcoin's infrastructure. Community discussion is amplified by news of companies like C2 Blockchain ($CBLO) significantly expanding their $DOG treasury holdings, signaling growing institutional interest and long-term conviction.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is generating significant buzz as investors keenly await its upcoming delivery report, with recent 'preemptive estimates' suggesting potentially lower vehicle numbers. This has ignited fierce debate, with bulls anticipating a short squeeze and long-term growth from its FSD, AI, and Cybercab ventures, while bears decry declining sales and unfulfilled technological promises, calling the stock overvalued.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull Corp (BULL) is trending as its inclusion in the Russell indexes vies for attention with persistent selling pressure, largely attributed to ongoing dilution from SPAC-related share agreements and year-end portfolio adjustments. Community sentiment is deeply divided, with optimists emphasizing the company's profitability and long-term growth potential, while skeptics highlight continuous price declines and concerns over further share dilution. This divergence underscores broader market debates on fintech valuations and the impact of SPAC-originated supply on stock performance.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is buzzing after securing FDA approval for NEREUS (tradipitant), marking the first new motion sickness drug in approximately 40 years. The community is highly engaged, primarily discussing the drug's significant potential as an add-on treatment for GLP-1 induced nausea, fueling widespread speculation of a substantial buyout from major pharmaceutical players. This pivotal approval, alongside other imminent pipeline catalysts, has many anticipating significant long-term growth despite initial market fluctuations.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics ($EKSO) is seeing a significant surge and exceptional trading volume following news of a proposed business combination with Applied Digital's Cloud business to form ChronoScale Corporation, focused on AI workloads. The community is actively debating the implications of this AI infrastructure play, with many highlighting its low float and anticipating further momentum from short squeezes. However, some voices express caution regarding potential dilution for existing shareholders and the long-term outlook of the combined entity.

ProShares Trust - ProShares Ultra Silver 2x Shares

ProShares Ultra Silver

ProShares Ultra Silver (AGQ) is trending amid a significant surge in silver prices, fueled by increasing industrial demand and speculation that silver is playing catch-up with gold's rally. The community is buzzing with predictions of further explosive gains and a 'silver squeeze,' though some express caution about extreme volatility and the potential for a sharp correction in this leveraged commodity.

Coupang, Inc. engages in the provision of retail, restaurant delivery, video streaming, and fintech services to customers around the world under brands that include Coupang, Coupang Eats, Coupang Play, and Farfetch. It operates through the Product Commerce and Developing Offerings segments. The Product Commerce segment consists of the company's core retail and marketplace offerings and Rocket Fresh, its fresh grocery category offering. It also includes advertising products associated with these offerings. The Developing Offerings segment covers the company's more nascent offerings and services including: Coupang Eats, a restaurant ordering and delivery service in Korea, Coupang Play, an online content streaming service in Korea, fintech services, retail operations in Taiwan, as well as advertising products associated with these offerings. It also includes Farfetch, a global luxury fashion marketplace. The company was founded by Bom Kim in 2010 and is headquartered in Seattle, WA.

Coupang Inc - Ordinary Shares - Class A

Coupang Inc 

Coupang is trending due to escalating controversy surrounding a significant data breach impacting millions of users and its perceived lack of transparency, drawing strong criticism from both Korean government officials and consumers. The community is vigorously discussing leadership's response and the potential for severe operational and financial repercussions, as mounting calls for boycotts and legal action cast a shadow over its future in its dominant market.

Direxion Shares ETF Trust - Direxion Daily Junior Gold Miners Index Bull 2X Shares

Direxion Daily Junior Gold Miners Index Bull 2X Shares

JNUG is actively trending amid widespread community discussion anticipating aggressive Fed rate cuts and potential quantitative easing, which some believe will further debase the dollar and fuel inflation. This outlook, combined with escalating global trade tensions and signs of economic fragility despite a rising equity market, is driving significant interest in gold and related mining assets as a perceived safe haven.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What's Going On With Greenwich LifeSciences Stock Monday?

Greenwich LifeSciences shares are trading higher Monday after the company announced it extended its lock-up period to Sept. 30, 2026.read more...

<ul class="summary-bullets"><li>During this period, insiders will be restricted from selling their shares unless the board decides otherwise.</li><li>The lock-up helps align insiders with long-term shareholders while supporting the Phase III FLAMINGO-01 study of GLSI-100, CEO Snehal Patel said.</li><li>GLSI shares have been on a rally since the company announced progress in the FLAMINGO-01 trial on December 15, gaining more than 130%.</li></ul>Shares of Greenwich LifeSciences Inc. (GLSI) jumped 25% on Monday, to their highest since February 2022, after the company’s Board extended the lock-up period on shares held by directors, officers, and pre-IPO investors&nbsp;by six months, through Sept. 30, 2026 – roughly six years after the company’s initial public offering (IPO).During this period, insiders will be restricted from selling their shares unless the board decides otherwise. Any sales after that date would still be limited under a structured “leak-out” plan.Chief Executive Officer Snehal Patel said the longer lock-up helps align insiders with long-term shareholders while supporting the Phase III FLAMINGO-01 study of GLSI-100, an immunotherapy to prevent breast cancer recurrence.<a href="https://stocktwits.com/symbol/GLSI">GLSI shares</a> have been on a rally since the company announced progress in the FLAMINGO-01 trial on December 15, gaining more than 130%.&nbsp; The stock is on track to post its biggest monthly gain in five years.<h2 class="st-heading-2">FLAMINGO-01 Trial Progress</h2>FLAMINGO-01 is a global Phase III study testing GLSI-100 in HER2-positive breast cancer patients following standard treatment. More than 1,000 patients have been screened, with enrollment continuing across U.S. and European sites, the company said. Around 140 sites are actively enrolling patients, with plans to expand further in 2026.Preliminary data from the open-label non-HLA-A*02 arm, involving 250 treated patients, showed around 80% reduction in recurrence rates following the primary immunization series, which consists of six injections over six months. These early results appear consistent with findings from the company’s Phase IIb trial, though Greenwich cautioned that the data remains preliminary and subject to further review.In its earlier Phase IIb trial, GLSI-100 demonstrated an 80% or greater reduction in metastatic breast cancer recurrences over five years in treated patients, with a strong immune response and a favorable safety profile. These results underpin the design and expectations of the ongoing Phase III study, the company added.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits remained in the ‘extremely bullish’ territory over the past 24 hours, amid ‘extremely high’ message volumes. GLSI was among the top trending tickers on the platform at the time of writing.<img src="https://news.stocktwits-cdn.com/GLSI_png_c5b2b8ee32.webp" alt="GLSI.png">One user believes that, given the large volume, a ‘big player’ could be buying in.<stembedurl>https://stocktwits.com/Whitevalkyrie01/message/640311249</stembedurl>Year-to-date, GLSI has gained more than 120%.Read Also: <a href="https://stocktwits.com/news-articles/markets/equity/copper-sees-strong-rally-this-year-but-consolidation-in-2026/cL75wm5RExf">Copper Saw A Massive Rally This Year – Goldman Sachs Sees Consolidation In 2026</a> For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Did GLSI Stock Surge 25% Today?

The company’s Board extended the lock-up on shares held by directors, officers, and pre-IPO investors through Sept. 30, 2026.

Equity

Greenwich LifeSciences (NASDAQ:GLSI) Raised to "Hold" at Wall Street Zen

Wall Street Zen raised Greenwich LifeSciences from a "sell" rating to a "hold" rating in a research report on Saturday...

What's Going On With Greenwich LifeSciences Friday?

Greenwich LifeSciences stock hits a new 52-week high! Discover how Greenwich LifeSciences is streamlining its Phase 3 FLAMINGO-01 trial.read more...

Snehal Patel Purchases 4,100 Shares of Greenwich LifeSciences (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel acquired 4,100 shares of the firm's stock in a transaction that occurred on Thursday, December 18th. The shares were...

Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Purchases 4,100 Shares of Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel purchased 4,100 shares of the firm's stock in a transaction on Thursday, December 18th. The stock was acquired at an...

<ul class="summary-bullets"><li>The company highlighted an 80% recurrence rate reduction in the open-label non-HLA-A*02 arm of the Phase III clinical trial.&nbsp;</li><li>The company noted that the latest observation trended similarly to its Phase IIb trial results and hazard ratio.</li></ul>Greenwich LifeSciences, Inc.’s (GLSI) shares soared in premarket trading on Monday after the company announced positive results from its phase III clinical trial, FLAMINGO-01, evaluating an immunotherapy to prevent breast cancer recurrences.Greenwich highlighted about an 80% recurrence rate reduction in the open-label non-HLA-A*02 arm of the Phase III clinical trial.Shares of <a href="https://stocktwits.com/symbol/GLSI">GLSI</a> were up over 86% premarket at the time of writing.<h2 class="st-heading-2">Trial Details</h2>The company noted that the latest observation trended similarly to its Phase IIb trial results and hazard ratio, where the patients were treated, and breast cancer recurrences were reduced up to 80% compared to a 20-50% reduction in recurrence rate by other approved products.“Despite these being preliminary results that will mature and can change with time, seeing a reduction in expected recurrence rates that is trending towards a low HR of 0.2, which represents an 80% reduction in recurrence rate, is very encouraging and which is why along with the similarly promising safety and immune response data to date, we will seek to continue to treat non-HLA-A*02 patients in a placebo controlled manner in the study," said CEO Snehal Patel.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, GLSI was the second-most trending stock on Monday morning. The retail sentiment around GLSI continued to trend in the ‘extremely bullish’ territory compared to ‘bullish’ a month ago, while message volume has remained ‘extremely high’ at the time of writing.<figure class="image"><img style="aspect-ratio:1279/145;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_15_at_5_07_16_PM_png_76f022ac17.webp" alt="Retail sentiment for GLSI at the time of writing was 'extremely bullish' and message volume was 'extremely high'." width="1279" height="145"></figure>One Stocktwits user said they would be watching the stock all day, indicating their bullish stance on the company.<stembedurl>https://stocktwits.com/Rolltide2020/message/639156747</stembedurl>Shares of GLSI are down over 16% over the last year.For updates and corrections, email newsroom[at]stocktwits[dot]com. &nbsp;

Mammogram imagery, regular mammogram on the left, and contrast enhanced mammogram on the right, on Thursday, Sept. 26, 2024 in Houston. (Brett Coomer/Houston Chronicle via Getty Images)

Why Is GLSI Stock Rising Today?

Greenwich LifeSciences shares surged following the company’s announcement of positive results from its phase III clinical trial, FLAMINGO-01. 

Why Is GLSI Stock Rising Today? 

Greenwich LifeSciences shares surged following the company’s announcement of positive results from its phase III clinical trial, FLAMINGO-01. 


Noble Financial Issues Pessimistic Outlook for GLSI Earnings

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Free Report) - Equities research analysts at Noble Financial decreased their FY2025 EPS estimates for Greenwich LifeSciences in a research note issued on...

Insider Buying: Greenwich LifeSciences (NASDAQ:GLSI) CEO Purchases $38,502.00 in Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel bought 4,600 shares of Greenwich LifeSciences stock in a transaction that occurred on Tuesday, November 25th. The stock...

Greenwich LifeSciences (NASDAQ:GLSI) Releases Earnings Results, Meets Expectations

Greenwich LifeSciences (NASDAQ:GLSI - Get Free Report) released its earnings results on Friday. The company reported ($0.30) EPS for the quarter, hitting the consensus estimate of ($0.30...

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

GLSI
Greenwich LifeSciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest GLSI News

GLSIGreenwich LifeSciences Inc